DDInter233 DDInter1435
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Brigatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ubrogepant
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Levonorgestrel
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Brigatinib may lead to a major life threatening interaction when taken with Levonorgestrel
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib